
Servier and MiNA Therapeutics sign €220m deal
Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

Moderna to file for EU approval of mRNA-1273 vaccine
Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...

Rentschler Biopharma to produce 100m doses of CureVac vaccine
Rentschler Biopharma SE is preparing large scale cGMP production and formulation of Curevac’s mRNA vaccine CVnCoV. Under a contract, signed in...

Germany first EU country to launch COVID-19 therapy offensive?
"Besides protection by masks, social distancing etc, rapid diagnostic testing, and COVID-19 vaccines, we are now establishing a fourth pillar of...

Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

Drug set to rescue COVID-19 patients at ICUs
Initial data from an US expanded access (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...